Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation

Peleg, 2008, Acinetobacter baumannii: emergence of a successful pathogen, Clin Microbiol Rev, 21, 538, 10.1128/CMR.00058-07 Neidell, 2012, Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms, Clin Infect Dis, 55, 807, 10.1093/cid/cis552 Lautenbach, 2009, Epidemiology and impact of imipenem resistance in Acinetobacter baumannii, Infect Control Hosp Epidemiol, 30, 1186, 10.1086/648450 Karageorgopoulos, 2008, Current control and treatment of multidrug-resistant Acinetobacter baumannii infections, Lancet Infect Dis, 8, 751, 10.1016/S1473-3099(08)70279-2 Ng, 2014, A multicenter case–case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia, Infect Control Hosp Epidemiol, 35, 49, 10.1086/674387 Cisneros, 2005, Risk‐factors for the acquisition of imipenem‐resistant Acinetobacter baumannii in Spain: a nationwide study, Clin Microbiol Infect, 11, 874, 10.1111/j.1469-0691.2005.01256.x Lee, 2017, Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options, Front Cell Infect Microbiol, 7, 55, 10.3389/fcimb.2017.00055 Bergogne-Bérézin, 1996, Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features, Clin Microbiol Rev, 9, 148, 10.1128/CMR.9.2.148 Bialvaei, 2017, Epidemiology of multidrug-resistant Acinetobacter baumannii strains in Iran: a systematic review and meta-analysis, J Chemother, 29, 327, 10.1080/1120009X.2017.1338377 Labarca, 2016, Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America, Crit Rev Microbiol, 42, 276 Cai, 2012, Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies, J Antimicrob Chemother, 67, 1607, 10.1093/jac/dks084 Liu, 2016, Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study, Lancet Infect Dis, 16, 161, 10.1016/S1473-3099(15)00424-7 Ni, 2013, In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii, J Antibiot (Tokyo), 66, 705, 10.1038/ja.2013.84 Principe, 2013, In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection, Microb Drug Resist, 19, 407, 10.1089/mdr.2012.0250 Sun, 2014, Synergistic efficacy of meropenem and rifampicin in a murine model of sepsis caused by multidrug-resistant Acinetobacter baumannii, Eur J Pharmacol, 729, 116, 10.1016/j.ejphar.2014.02.015 Phee, 2015, Colistin and fusidic acid: a novel potent synergistic combination for the treatment of multidrug-resistant Acinetobacter baumannii infections, Antimicrob Agents Chemother, 59, 4544, 10.1128/AAC.00753-15 Majewski, 2014, In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the blaOXA-72 resistance gene, Scand J Infect Dis, 46, 260, 10.3109/00365548.2013.865141 Liu, 2015, In vitro activity of tigecycline in combination with cefoperazone–sulbactam against multidrug-resistant Acinetobacter baumannii, J Chemother, 27, 271, 10.1179/1973947814Y.0000000203 Galani, 2014, Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii, Int J Antimicrob Agents, 43, 370, 10.1016/j.ijantimicag.2013.12.010 Liu, 2014, Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii, Rev Soc Bras Med Trop, 47, 451, 10.1590/0037-8682-0081-2014 Wareham, 2011, In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii, J Antimicrob Chemother, 66, 1047, 10.1093/jac/dkr069 Safarika, 2015, Time–kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin, Eur J Clin Microbiol Infect Dis, 34, 317, 10.1007/s10096-014-2231-7 Kiratisin, 2010, Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates, Int J Antimicrob Agents, 36, 243, 10.1016/j.ijantimicag.2010.04.011 Park, 2016, In vitro interactions of antibiotic combinations of colistin, tigecycline, and doripenem against extensively drug-resistant and multidrug-resistant Acinetobacter baumannii, Ann Lab Med, 36, 124, 10.3343/alm.2016.36.2.124 Bai, 2015, In vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 59, 1466, 10.1128/AAC.04089-14 Rodríguez, 2015, In vitro activity of minocycline alone or in combination in multidrug-resistant Acinetobacter baumannii isolates, J Med Microbiol, 64, 1196, 10.1099/jmm.0.000147 Lim, 2011, In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore, PLoS One, 6, e18485, 10.1371/journal.pone.0018485 Rodriguez, 2010, In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones, J Infect Dev Ctries, 4, 164, 10.3855/jidc.604 Pongpech, 2011, Antibacterial activity of carbapenem-based combinations against multidrug-resistant Acinetobacter baumannii, J Med Assoc Thai, 93, 161 Nageeb, 2015, In vitro antimicrobial synergy studies of carbapenem-resistant Acinetobacter baumannii isolated from intensive care units of a tertiary care hospital in Egypt, J Infect Public Health, 8, 593, 10.1016/j.jiph.2015.05.007 Menegucci, 2016, Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections, Int J Antimicrob Agents, 47, 380, 10.1016/j.ijantimicag.2016.02.007 Lee, 2008, Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia, Microb Drug Resist, 14, 233, 10.1089/mdr.2008.0840 Principe, 2009, In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii, Ann Clin Microbiol Antimicrob, 8, 18, 10.1186/1476-0711-8-18 Lim, 2009, In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore, J Antibiot (Tokyo), 62, 675, 10.1038/ja.2009.99 Wei, 2017, Activity of levofloxacin in combination with colistin against Acinetobacter baumannii: in vitro and in a Galleria mellonella model, J Microbiol Immunol Infect, 50, 821, 10.1016/j.jmii.2015.10.010 Gordon, 2010, Potent synergy and sustained bactericidal activity of a vancomycin–colistin combination versus multidrug-resistant strains of Acinetobacter baumannii, Antimicrob Agents Chemother, 54, 5316, 10.1128/AAC.00922-10 Marie, 2015, A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii, Bosn J Basic Med Sci, 15, 24 Deveci, 2012, In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates, J Chemother, 24, 247, 10.1179/1973947812Y.0000000029 Kaya, 2017, Evaluation of the synergistic effect of a combination of colistin and tigecycline against multidrug-resistant Acinetobacter baumannii, Pak J Med Sci, 33, 393 Phee, 2013, In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens, Eur J Clin Microbiol Infect Dis, 32, 1291, 10.1007/s10096-013-1875-z Arroyo, 2009, In vitro activities of tigecycline, minocycline, and colistin–tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group, Antimicrob Agents Chemother, 53, 1295, 10.1128/AAC.01097-08 Sheng, 2011, Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU, Diagn Microbiol Infect Dis, 70, 380, 10.1016/j.diagmicrobio.2011.03.003 Le Minh, 2015, In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam, J Med Microbiol, 64, 1162, 10.1099/jmm.0.000137 Santimaleeworagun, 2011, In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases, Southeast Asian J Trop Med Public Health, 42, 890 O'Hara, 2013, Activity of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains, Antimicrob Agents Chemother, 57, 2103, 10.1128/AAC.02501-12 Karaoglan, 2013, In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii, J Int Med Res, 41, 1830, 10.1177/0300060513496172 Liang, 2011, Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients, BMC Infect Dis, 11, 109, 10.1186/1471-2334-11-109 Dizbay, 2010, In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii, J Antibiot (Tokyo), 63, 51, 10.1038/ja.2009.117 García-Salguero, 2015, Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii?, Antimicrob Agents Chemother, 59, 5959, 10.1128/AAC.00873-15 Pei, 2012, In vitro activity of minocycline alone and in combination with cefoperazone–sulbactam against carbapenem-resistant Acinetobacter baumannii, Microb Drug Resist, 18, 574, 10.1089/mdr.2012.0076 Zhu, 2018, In vitro evaluation of antimicrobial combinations against imipenem-resistant Acinetobacter baumannii of different MICs, J Infect Public Health, 11, 856, 10.1016/j.jiph.2018.07.006 Cikman, 2015, In vitro activity of colistin in combination with tigecycline against carbapenem-resistant Acinetobacter baumannii strains isolated from patients with ventilator-associated pneumonia, Int J Med Sci, 12, 695, 10.7150/ijms.11988 Temocin, 2015, Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii, Braz J Microbiol, 46, 1119, 10.1590/S1517-838246420140101 Hong, 2016, In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates, Diagn Microbiol Infect Dis, 86, 184, 10.1016/j.diagmicrobio.2016.07.017 Yang, 2016, In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 60, 4047, 10.1128/AAC.02994-15 Wei, 2016, In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase, J Chemother, 28, 159, 10.1179/1973947815Y.0000000030 Lee, 2016, In vitro synergistic effects of antimicrobial combinations on extensively drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates, Ann Lab Med, 36, 138, 10.3343/alm.2016.36.2.138 Zhang, 2013, In vitro antibacterial activity of combinations of fosfomycin, minocycline and polymyxin B on pan-drug-resistant Acinetobacter baumannii, Exp Ther Med, 5, 1737, 10.3892/etm.2013.1039 Madadi-Goli, 2017, Sensitivity of levofloxacin in combination with ampicillin–sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii, Iran J Microbiol, 9, 19 Wei, 2017, Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: colistin and chloramphenicol, Int J Antimicrob Agents, 49, 321, 10.1016/j.ijantimicag.2016.11.031 Li, 2018, In vitro assessment of cefoperazone–sulbactam based combination therapy for multidrug-resistant Acinetobacter baumannii isolates in China, J Thorac Dis, 10, 1370, 10.21037/jtd.2018.02.01 Liu, 2016, Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model, Int J Antimicrob Agents, 48, 559, 10.1016/j.ijantimicag.2016.07.018 Matuschek, 2018, Antimicrobial susceptibility testing of colistin—evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp, Clin Microbiol Infect, 24, 865, 10.1016/j.cmi.2017.11.020 Dinc, 2013, Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis, Chemotherapy, 59, 325, 10.1159/000356755 Monogue, 2018, Humanized exposures of a β-lactam–β-lactamase inhibitor, tazobactam, versus non-β-lactam–β-lactamase inhibitor, avibactam, with or without colistin, against Acinetobacter baumannii in murine thigh and lung infection models, Pharmacology, 101, 255, 10.1159/000486445 Song, 2009, Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model, Int J Antimicrob Agents, 33, 33, 10.1016/j.ijantimicag.2008.07.008 Pachón-Ibáñez, 2010, Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 54, 1165, 10.1128/AAC.00367-09 Bowers, 2015, Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii, Antimicrob Agents Chemother, 59, 2720, 10.1128/AAC.04110-14 Yilmaz, 2012, Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii, Int J Antimicrob Agents, 40, 332, 10.1016/j.ijantimicag.2012.06.003 Queenan, 2013, Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients, J Chemother, 25, 141, 10.1179/1973947813Y.0000000074 Fan, 2016, Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model, PLoS One, 11, 10.1371/journal.pone.0157757 Yang, 2015, In vivo activity of daptomycin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection, Int J Antimicrob Agents, 45, 188, 10.1016/j.ijantimicag.2014.10.012 Yang, 2016, In vivo activity of vancomycin combined with colistin against multidrug-resistant strains of Acinetobacter baumannii in a Galleria mellonella model, Infect Dis (Lond), 48, 189, 10.3109/23744235.2015.1103894 Hornsey, 2011, In vivo efficacy of glycopeptide/colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection, Antimicrob Agents Chemother, 55, 3534, 10.1128/AAC.00230-11 2016 Petrosillo, 2014, Clinical experience of colistin–glycopeptide combination in critically ill patients infected with Gram-negative bacteria, Antimicrob Agents Chemother, 58, 851, 10.1128/AAC.00871-13 Kalin, 2014, Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, Infection, 42, 37, 10.1007/s15010-013-0495-y López-Cortés, 2014, Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort, J Antimicrob Chemother, 69, 3119, 10.1093/jac/dku233 Balkan, 2015, Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis, Indian J Pharmacol, 47, 95, 10.4103/0253-7613.150383 Yilmaz, 2015, Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia, J Infect Dev Ctries, 9, 476, 10.3855/jidc.6195 Garnacho-Montero, 2013, Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii, Chemotherapy, 59, 225, 10.1159/000356004 Rigatto, 2015, Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections, Antimicrob Agents Chemother, 59, 6575, 10.1128/AAC.00494-15 Batirel, 2014, Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections, Eur J Clin Microbiol Infect Dis, 33, 1311, 10.1007/s10096-014-2070-6 Lin, 2015, Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus–Acinetobacter baumannii complex, Infect Dis (Lond), 47, 370, 10.3109/00365548.2014.995129 Shin, 2012, Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection, Yonsei Med J, 53, 974, 10.3349/ymj.2012.53.5.974 Tasbakan, 2011, Is tigecycline a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia?, J Chemother, 23, 345, 10.1179/joc.2011.23.6.345 Kim, 2016, Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients, PLoS One, 11 Lee, 2013, Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections, Eur J Clin Microbiol Infect Dis, 32, 1211, 10.1007/s10096-013-1870-4 Lim, 2011, The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections, J Korean Med Sci, 26, 325, 10.3346/jkms.2011.26.3.325 Ye, 2016, Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus–Acinetobacter baumannii complex, BMC Infect Dis, 16, 374, 10.1186/s12879-016-1717-6 Chuang, 2014, Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis, BMC Infect Dis, 14, 102, 10.1186/1471-2334-14-102 Cheng, 2015, Excess mortality associated with colistin–tigecycline compared with colistin–carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study, Crit Care Med, 43, 1194, 10.1097/CCM.0000000000000933 Jean, 2016, J Microbiol Immunol Infect, 49, 924, 10.1016/j.jmii.2015.06.009 He, 2016, Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii, J Thorac Dis, 8, 2784, 10.21037/jtd.2016.10.29 Chen, 2014, Influencing factors of successful eradication of multidrug-resistant Acinetobacter baumannii in the respiratory tract with aerosolized colistin, Biomed J, 37, 314, 10.4103/2319-4170.132879 Kuo, 2012, Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case–control study, Clin Microbiol Infect, 18, 870, 10.1111/j.1469-0691.2011.03682.x Jang, 2017, Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii, J Crit Care, 40, 251, 10.1016/j.jcrc.2017.04.004 Kofteridis, 2010, Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case–control study, Clin Infect Dis, 51, 1238, 10.1086/657242 Kalin, 2012, Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?, J Infect Chemother, 18, 872, 10.1007/s10156-012-0430-7 Pan, 2018, Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinetobacter baumannii: a retrospective cohort study, Antimicrob Resist Infect Control, 7, 8, 10.1186/s13756-018-0305-5 Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291 Yapa, 2014, Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration, Antimicrob Agents Chemother, 58, 2570, 10.1128/AAC.01705-13 Rattanaumpawan, 2010, Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria, J Antimicrob Chemother, 65, 2645, 10.1093/jac/dkq360 Paul, 2018, Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial, Lancet Infect Dis, 18, 391, 10.1016/S1473-3099(18)30099-9 Durante-Mangoni, 2013, Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin Infect Dis, 57, 349, 10.1093/cid/cit253 Aydemir, 2013, Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia, Epidemiol Infect, 141, 1214, 10.1017/S095026881200194X Sirijatuphat, 2014, Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections, Antimicrob Agents Chemother, 58, 5598, 10.1128/AAC.02435-13 Makris, 2018, Colistin versus colistin combined with ampicillin–sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study, Indian J Crit Care Med, 22, 67, 10.4103/ijccm.IJCCM_302_17 Abdellatif, 2016, Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial, Ann Intensive Care, 6, 26, 10.1186/s13613-016-0127-7 Betrosian, 2008, Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, J Infect, 56, 432, 10.1016/j.jinf.2008.04.002 Dickstein, 2018, Treatment outcomes of colistin and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial, Clin Infect Dis Preston, 2004, The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations, Ann Pharmacother, 38, S14, 10.1345/aph.1E218 Levison, 2009, Pharmacokinetics and pharmacodynamics of antibacterial agents, Infect Dis Clin North Am, 23, 791, 10.1016/j.idc.2009.06.008 Craig, 2001, Pharmacodynamics of antimicrobials: general concepts and applications, 1 Hagihara, 2014, In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 58, 874, 10.1128/AAC.01624-13 Li, 2014, Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model, Antimicrob Agents Chemother, 58, 6776, 10.1128/AAC.03505-14 Cai, 2017, Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model, Int J Antimicrob Agents, 49, 609, 10.1016/j.ijantimicag.2017.01.007 Matsumoto, 2017, Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics, Antimicrob Agents Chemother, 64 Lee, 2013, Synergistic activity of colistin and rifampicin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model, Antimicrob Agents Chemother, 57, 3738, 10.1128/AAC.00703-13 Housman, 2013, In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii, J Antimicrob Chemother, 68, 2296 Rao, 2016, Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies, J Antimicrob Chemother, 71, 3148, 10.1093/jac/dkw293 Lenhard, 2017, High-dose ampicillin–sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model, Antimicrob Agents Chemother, 61, 10.1128/AAC.01268-16 Roberts, 2009, Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution, J Antimicrob Chemother, 64, 142, 10.1093/jac/dkp139 Nicholson, 2009, Doripenem 1 g infused for 4 hours in the treatment of nosocomial pneumonia/ventilator associated pneumonia (NP/VAP) due to Acinetobacter baumannii (A. baumannii) Jaruratanasirikul, 2013, Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia, J Med Assoc Thai, 96, 1283 Jaruratanasirikul, 2016, Population pharmacokinetics and pharmacodynamics modeling to optimize dosage regimens of sulbactam in critically ill patients with severe sepsis caused by Acinetobacter baumannii, Antimicrob Agents Chemother, 60, 7236, 10.1128/AAC.01669-16 Xie, 2014, Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation, Int J Infect Dis, 18, 62, 10.1016/j.ijid.2013.09.008 Mouton, 2005, Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update, J Antimicrob Chemother, 55, 601, 10.1093/jac/dki079 Yokoyama, 2014, Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models, Int J Antimicrob Agents, 43, 547, 10.1016/j.ijantimicag.2014.02.012 Yokoyama, 2015, Population pharmacokinetic–pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections, J Infect Chemother, 21, 284, 10.1016/j.jiac.2014.12.005 Dudhani, 2010, fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models, J Antimicrob Chemother, 65, 1984, 10.1093/jac/dkq226 Nation, 2016, Dosing guidance for intravenous colistin in critically ill patients, Clin Infect Dis, 64, 565 Nation, 2015, Updated US and European dose recommendations for intravenous colistin: how do they perform?, Clin Infect Dis, 62, 552, 10.1093/cid/civ964 Maglio, 2005, Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model, Antimicrob Agents Chemother, 49, 276, 10.1128/AAC.49.1.276-280.2005 MacVane, 2014, Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations, Antimicrob Agents Chemother, 58, 599, 10.1128/AAC.02029-13 Joukhadar, 2003, Target site penetration of fosfomycin in critically ill patients, J Antimicrob Chemother, 51, 1247, 10.1093/jac/dkg187 Meagher, 2007, Exposure–response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections, Antimicrob Agents Chemother, 51, 1939, 10.1128/AAC.01084-06 Passarell, 2008, Exposure–response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections, Antimicrob Agents Chemother, 52, 204, 10.1128/AAC.00813-07 Craig, 1998, Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, Clin Infect Dis, 26, 1, 10.1086/516284 Chan, 2010, Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia, J Intensive Care Med, 25, 343, 10.1177/0885066610377975 Wood, 2003, Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia, Intensive Care Med, 29, 2072, 10.1007/s00134-003-1811-2 Bishburg, 2014, Use of intravenous minocycline for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) and resistant Gram-negative organisms: experience in a tertiary care hospital, Infect Dis Clin Pract, 22, 26, 10.1097/IPC.0b013e31828bbb82 Katsube, 2017, Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function, Antimicrob Agents Chemother, 61, 10.1128/AAC.01381-16 Van Wart, 2013, Pharmacokinetic/pharmacodynamic (PK/PD) assessment predicts high efficacy for plazomicin against serious infections caused by carbapenem-resistant Klebsiella pneumoniae (CR Kp) O'Donnell, 2016, Human pharmacokinetics and dose projection of ETX2514/sulbactam combination for use in the treatment of infections caused by Acinetobacter baumannii, Open Forum Infect Dis, 3, 2445 Lepak, 2016, In vivo pharmacodynamic target assessment of delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model, Antimicrob Agents Chemother, 60, 4764, 10.1128/AAC.00647-16 Thabit, 2016, Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens, Int J Antimicrob Agents, 48, 535, 10.1016/j.ijantimicag.2016.08.012 Ghazi, 2018, Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model, Int J Antimicrob Agents, 51, 206, 10.1016/j.ijantimicag.2017.10.008 Zhao, 2017, In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model, Antimicrob Agents Chemother, 61, 10.1128/AAC.00250-17 Flamm, 2014, Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)., J Antimicrob Chemother, 69, 1589, 10.1093/jac/dku025 Flamm, 2016, In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients, Int J Antimicrob Agents, 47, 235, 10.1016/j.ijantimicag.2016.01.004 Sader, 2017, WCK 5222 (cefepime–zidebactam) antimicrobial activity tested against clinical isolates of Gram-negative bacteria collected worldwide in 2015, Antimicrob Agents Chemother, 61, 10.1128/AAC.00072-17 Livermore, 2017, In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria, J Antimicrob Chemother, 72, 1373, 10.1093/jac/dkw593 Lob, 2017, In vitro activity of imipenem–relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program), Antimicrob Agents Chemother, 61, e02209, 10.1128/AAC.02209-16 Lapuebla, 2015, Activity of imipenem with relebactam against Gram-negative pathogens from New York City, Antimicrob Agents Chemother, 59, 5029, 10.1128/AAC.00830-15 Castanheira, 2017, Meropenem–vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae, Antimicrob Agents Chemother, 61, 10.1128/AAC.00567-17 Biedenbach, 2015, In vitro activity of aztreonam–avibactam against a global collection of Gram-negative pathogens from 2012 and 2013, Antimicrob Agents Chemother, 59, 4239, 10.1128/AAC.00206-15 Testa, 2015, In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates, Int J Antimicrob Agents, 45, 641, 10.1016/j.ijantimicag.2014.12.033 Yoshizumi, 2015, In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime–, ceftaroline–, and aztreonam–avibactam combinations, J Infect Chemother, 21, 148, 10.1016/j.jiac.2014.08.028 Wang, 2014, In vitro activities of ceftazidime–avibactam and aztreonam–avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China, Antimicrob Agents Chemother, 58, 1774, 10.1128/AAC.02123-13 Ito, 2017, In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria, Antimicrob Agents Chemother, 62, 10.1128/AAC.01454-17 Falagas, 2017, Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals, J Antimicrob Chemother, 72, 1704, 10.1093/jac/dkx049 Ito, 2015, In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria, J Antimicrob Chemother, 71, 670, 10.1093/jac/dkv402 Dobias, 2017, Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens, Eur J Clin Microbiol Infect Dis, 36, 2319, 10.1007/s10096-017-3063-z Hackel, 2017, In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study), Antimicrob Agents Chemother, 61, 10.1128/AAC.00093-17 Hackel, 2018, In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016, Antimicrob Agents Chemother, 62, 10.1128/AAC.01968-17 Landman, 2010, Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City, J Antimicrob Chemother, 66, 332, 10.1093/jac/dkq459 Kang, 2017, In vitro apramycin activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, Diagn Microbiol Infect Dis, 88, 188, 10.1016/j.diagmicrobio.2017.03.006 Livermore, 2016, In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii, Antimicrob Agents Chemother, 60, 3840, 10.1128/AAC.00436-16 Abdallah, 2015, Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City, Antimicrob Agents Chemother, 59, 1802, 10.1128/AAC.04809-14 Seifert, 2018, In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii, Int J Antimicrob Agents, 51, 62, 10.1016/j.ijantimicag.2017.06.022 Vázquez-Ucha, 2017, Activity of the β-lactamase inhibitor LN-1-255 against carbapenem-hydrolyzing class D β-lactamases from Acinetobacter baumannii, Antimicrob Agents Chemother, 61, 10.1128/AAC.01172-17 Mushtaq, 2017, WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases, J Antimicrob Chemother, 72, 1688, 10.1093/jac/dkx035 Durand-Réville, 2017, ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii, Nat Microbiol, 2, 17104, 10.1038/nmicrobiol.2017.104 Almer, 2004, In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms, Antimicrob Agents Chemother, 48, 2771, 10.1128/AAC.48.7.2771-2777.2004 Pfaller, 2017, In vitro activity of delafloxacin when tested against contemporary bacterial pathogens from the United States and Europe, 2014, Antimicrob Agents Chemother, 61, 10.1128/AAC.02609-16 Hirano, 2018, Discovery of a novel fluoroquinolone antibiotic candidate WFQ-228 with potent antimicrobial activity and the potential to overcome major drug resistance, Chem Pharm Bull (Tokyo), 66, 235, 10.1248/cpb.c17-00717 Seifert, 2017, In vitro activity of the novel fluorocycline TP-6076 against carbapenem non-susceptible Acinetobacter baumannii Zurawski, 2017, SPR741, an antibiotic adjuvant, potentiates the in vitro and in vivo activity of rifampin against clinically relevant extensively drug-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 61, 10.1128/AAC.01239-17 Corbett, 2017, Potentiation of antibiotic activity by a novel cationic peptide: potency and spectrum of activity of SPR741, Antimicrob Agents Chemother, 61, 10.1128/AAC.00200-17 Van Wart, 2013, Pharmacokinetic–pharmacodynamic analysis predicts a high probability of efficacy for plazomicin against serious infections caused by carbapenem-resistant Enterobacteriaceae Thabit, 2018, Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis, Int J Antimicrob Agents, 51, 727, 10.1016/j.ijantimicag.2018.01.001 Möllmann, 2009, Siderophores as drug delivery agents: application of the ‘Trojan horse’ strategy, Biometals, 22, 615, 10.1007/s10534-009-9219-2 Ito, 2015, S-649266, a novel siderophore cephalosporin: binding affinity to PBP and bactericidal activity Kohira, 2016, In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains, Antimicrob Agents Chemother, 60, 729, 10.1128/AAC.01695-15 Ito-Horiyama, 2016, Stability of novel siderophore cephalosporin S-649266 to clinically relevant carbapenemases, Antimicrob Agents Chemother, 60, 4384, 10.1128/AAC.03098-15 Horiyama, 2014, A novel siderophore cephalosporin: VI. Magnitude of PK/PD parameter required for efficacy in murine lung infection model Tsuji, 2016, S-649266, a novel siderophore cephalosporin: pharmacodynamic assessment by using MIC in iron-depleted cation-adjusted Mueller Hinton broth (ID-CAMHB), Open Forum Infect Dis, 3, 1995, 10.1093/ofid/ofw172.1543 Aggen, 2010, Synthesis and spectrum of the neoglycoside ACHN-490, Antimicrob Agents Chemother, 54, 4636, 10.1128/AAC.00572-10 Grossman, 2012, Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic, Antimicrob Agents Chemother, 56, 2559, 10.1128/AAC.06187-11 Weiss, 2010, Efficacy of fluorocycline TP-434 in the neutropenic thigh infection model is predicted by AUC/MIC